Program
LY4395089
A development code.
In Eli Lilly's pipeline, FXR agonist
. Its studies are mostly in Crohn Disease · Colitis, Ulcerative, led by Eli Lilly.
Furthest: phase 2, since Mar 16, 20263 company-led studies, 2 open or runningNext primary completion: Jun 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 32 open or running | phase 2since Mar 16, 2026 | Mar 16, 2026 | Jun 2027phase 2 · NCT07483099 |
- Named in Eli Lilly’s own pipeline as
FXR Agonist + Mirikizumab
, phase 2, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 16, 2026First studies: 2 phase 2 studiesFirst studyNCT07483099, NCT07483073
- May 12, 2026Phase 1 study in HealthyNCT07592572 · 14 enrolled · United States
Ahead
- Jun 2027Primary completion: phase 2 study in Crohn DiseaseNCT07483099
- Jun 2027Primary completion: phase 2 study in Colitis, UlcerativeNCT07483073
TargetBeta
“FXR agonist”the company's pipeline, read by Claude · source
“The main purpose of this study is to see how the safety and efficacy of a farnesoid X receptor (FXR) agonist (LY4395089), given together with mirikizumab compares with mirikizumab (alone) in adults with moderately to severely active Crohn's disease (CD).”study summary, read by Claude · the study
Other programs on NR1H4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cilofexorrule | Gilead Sciences | phase 3 | 13 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07592572Healthy · United States | 1 | Completed | Jul 8, 2026 | 14 |
| NCT07483099Crohn Disease · United States, Belgium, Brazil and more | 2 | Recruiting | Jun 2027 | 60 |
| NCT07483073Colitis, Ulcerative · United States, Belgium, Brazil and more | 2 | Recruiting | Jun 2027 | 60 |
How it is read
Names in the registry
- “LY4395089”, 3 entries
Codes read as this program: LY4395089.
Conditions, from the studies’ own filings
- Crohn Disease, 1 study
- Colitis, Ulcerative, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.